Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays

J Med Chem. 2004 Dec 30;47(27):6658-61. doi: 10.1021/jm049486a.

Abstract

A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Dasatinib
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • K562 Cells
  • Mice
  • Proto-Oncogene Proteins c-abl / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-abl / chemistry
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Thiazoles / pharmacokinetics
  • Thiazoles / pharmacology*
  • src-Family Kinases / antagonists & inhibitors*
  • src-Family Kinases / chemistry

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Pyrimidines
  • Thiazoles
  • Adenosine Triphosphate
  • Proto-Oncogene Proteins c-abl
  • src-Family Kinases
  • Dasatinib